The committee also noted three extensions of pre-existing therapies.
News
Subcutaneous Remsima launched in UK
The new option is the first and only subcutaneous formulation of the drug.
Trelegy Ellipta filing accepted by EMA for asthma
As it stands there is no single inhaled triple therapy available for the treatment of asthma in Europe.
Bicycle, Roche collab for immuno-oncology therapies
Under the terms of the agreement, the companies will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
European partnerships to ‘accelerate’ cancer research
The project will look at rare and hard-to-treat cancers, helping to find better ways to treat them.
Biogen, Sangamo team up on neurological diseases
The companies have detailed plans to leverage Sangamo’s proprietary zinc finger protein (ZFP) technology.
Only 2 weeks left until CROY 2020 closes for entry
The 2020 Clinical Researcher of the Year – The Americas competition will be closing for entry on the 13th March.
Study finds industry ‘paying price’ for ill-prepared negotiators
The pharma industry is launching into deals “ill-prepared”, Scotwork claims.
TrakCel, Ori Biotech ink supply chain deal for cell and gene therapy
TrakCel was created in 2012 in order to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain.
Revlimid gets NICE nod for lymphoma
The decision brings a new option to the market for around 900 patients.
Sanofi creates European drug ingredients business
When completed, the planned company will allegedly rank as the world’s second largest API company with approximately €1 billion in expected sales by 2022.
Gilead to kickstart remdesivir coronavirus trial
The hopeful drug in question is Gilead’s investigational broad-spectrum antiviral treatment that was previously tested in humans with Ebola virus.
Santen EMEA announces RWD on Taptiqom
Taptiqom was efficient in patients with insufficiently controlled open-angle glaucoma (OAG) and ocular hypertension (OHT).
Takeda acquires PvP Biologics
The acquisition follows the conclusion of a Phase I proof-of-mechanism study of investigational medicine TAK-062.
Polivy struck by NICE ‘no’
NICE is citing “substantial uncertainty in the submitted data” as a reason not to recommend the drug, as well as a lack of “strong long-term evidence on remission with the treatment.”
